A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett’s Esophagus

PURPOSE: This study evaluates the cost-effectiveness of a quantitative multi-biomarker assay (the Assay) that stratifies patients with Barrett’s Esophagus (BE) by risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) and can be used to guide clinical decisions, versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Jing, Critchley-Thorne, Rebecca, Diehl, David L, Snyder, Susan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818671/
https://www.ncbi.nlm.nih.gov/pubmed/31749626
http://dx.doi.org/10.2147/CEOR.S221741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818671/
https://www.ncbi.nlm.nih.gov/pubmed/31749626
http://dx.doi.org/10.2147/CEOR.S221741

Ejemplares similares